Jay N Cohn

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi request reprint Identifying the risk and preventing the consequences of cardiovascular disease
    Jay N Cohn
    University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Heart Lung Circ 22:512-6. 2013
  2. ncbi request reprint Monitoring vascular health beyond blood pressure
    Daniel A Duprez
    Rasmussen Center for Cardiovascular Disease Prevention, Medical School, University of Minnesota, 420 Delaware Street SE, Minneapolis, 55455, USA
    Curr Hypertens Rep 8:287-91. 2006
  3. doi request reprint Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia
    Jay N Cohn
    Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Hypertens 22:137-44. 2009
  4. doi request reprint Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Jay N Cohn
    University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Nat Clin Pract Cardiovasc Med 5:526-7. 2008
  5. doi request reprint Time to foster a rational approach to preventing cardiovascular morbid events
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 52:327-9. 2008
  6. ncbi request reprint Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 108:1306-9. 2003
  7. ncbi request reprint Screening for early detection of cardiovascular disease in asymptomatic individuals
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minn, USA
    Am Heart J 146:679-85. 2003
  8. ncbi request reprint Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Eur J Heart Fail 5:659-67. 2003
  9. ncbi request reprint Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesoata 55455, USA
    J Renin Angiotensin Aldosterone Syst 4:137-9. 2003
  10. ncbi request reprint The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 109:2256-62. 2004

Collaborators

Detail Information

Publications97

  1. doi request reprint Identifying the risk and preventing the consequences of cardiovascular disease
    Jay N Cohn
    University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Heart Lung Circ 22:512-6. 2013
    ..Therapy aimed at restoring vascular and cardiac health shows great promise as an individualised approach to cardiovascular disease prevention. ..
  2. ncbi request reprint Monitoring vascular health beyond blood pressure
    Daniel A Duprez
    Rasmussen Center for Cardiovascular Disease Prevention, Medical School, University of Minnesota, 420 Delaware Street SE, Minneapolis, 55455, USA
    Curr Hypertens Rep 8:287-91. 2006
    ....
  3. doi request reprint Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia
    Jay N Cohn
    Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Hypertens 22:137-44. 2009
    ..This nested substudy of the AVALON trial assessed the effects of coadministered amlodipine and atorvastatin vs. either therapy alone or placebo on arterial compliance, to evaluate the vascular benefits of coadministered therapy...
  4. doi request reprint Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Jay N Cohn
    University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Nat Clin Pract Cardiovasc Med 5:526-7. 2008
    ..Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other...
  5. doi request reprint Time to foster a rational approach to preventing cardiovascular morbid events
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 52:327-9. 2008
    ..More extensive data to confirm the sensitivity and specificity of this scoring system and to demonstrate its utility in tracking the response to therapy are needed to justify widespread application in clinical practice...
  6. ncbi request reprint Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 108:1306-9. 2003
    ..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure...
  7. ncbi request reprint Screening for early detection of cardiovascular disease in asymptomatic individuals
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minn, USA
    Am Heart J 146:679-85. 2003
    ..The objective of the current study is to screen individuals with vascular and cardiac tests aimed at identifying early abnormalities likely to progress and to measure risk contributors susceptible to therapy...
  8. ncbi request reprint Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Eur J Heart Fail 5:659-67. 2003
    ....
  9. ncbi request reprint Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesoata 55455, USA
    J Renin Angiotensin Aldosterone Syst 4:137-9. 2003
    ....
  10. ncbi request reprint The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 109:2256-62. 2004
  11. ncbi request reprint Surrogate markers for cardiovascular disease: functional markers
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, Minn 55455, USA
    Circulation 109:IV31-46. 2004
  12. ncbi request reprint Efficacy and safety in clinical trials in cardiovascular disease
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 48:430-3. 2006
    ..This revised approach, made possible by our enhanced ability to monitor the progression of disease, should make it possible to study earlier disease and to improve cardiovascular health while reducing health care costs...
  13. ncbi request reprint Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Hypertension 46:217-20. 2005
    ....
  14. ncbi request reprint Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA
    Am J Cardiol 97:4F-12F. 2006
    ..A review of animal and human studies with aldosterone blockers reveals improvement in, and in some cases complete reversal of, these pathophysiologic effects of aldosterone on the cardiovascular system...
  15. ncbi request reprint Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Congest Heart Fail 12:127-31. 2006
    ..The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1% per year...
  16. doi request reprint Comprehensive noninvasive arterial vascular evaluation
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, Minneapolis, MN 55455, USA
    Future Cardiol 5:573-9. 2009
    ..This can provide insight into functional and structural abnormalities in the small as well as the large arteries, and may be useful in monitoring response to therapy...
  17. doi request reprint Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
    Jay Cohn
    Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Card Fail 15:199-205. 2009
    ..Other end points are now being considered and implemented because of the recognized limitations associated with using mortality and morbidity as the sole measures of therapeutic efficacy...
  18. pmc A-HeFT: old dog, new endothelial tricks
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Tex Heart Inst J 32:366-8. 2005
    ..The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study...
  19. ncbi request reprint New approaches to screening for vascular and cardiac risk
    J N Cohn
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Am J Hypertens 14:218S-220S. 2001
    ..The usefulness of these early screening techniques to encourage tailored interventions in susceptible individuals needs to be explored in large-scale trials...
  20. doi request reprint Should the blood pressure or the blood vessel be the target of therapy?
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Expert Rev Cardiovasc Ther 9:1397-401. 2011
    ....
  21. doi request reprint Direct-acting vasodilators
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN, USA
    J Clin Hypertens (Greenwich) 13:690-2. 2011
    ..Although nitrates have not achieved widespread use as antihypertensive agents, they are effective in producing sustained blood pressure (BP) reductions when added to other antihypertensive regimens...
  22. ncbi request reprint Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro position
    Jay N Cohn
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Curr Hypertens Rep 4:307-10. 2002
    ..These data emphasize the need for trials in black patients to identify effective therapy. The first such trial, African-American Heart Failure Trial, is currently underway...
  23. ncbi request reprint Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Circulation 115:1747-53. 2007
    ....
  24. ncbi request reprint Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial
    Inder S Anand
    VA Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 49:32-9. 2007
    ....
  25. ncbi request reprint C-reactive protein in heart failure: prognostic value and the effect of valsartan
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1428-34. 2005
    ..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan...
  26. doi request reprint Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial
    Anne L Taylor
    Department of Medicine, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032, USA
    J Card Fail 18:600-6. 2012
    ..In this analysis, we investigated treatment effects by age <65 or ≥65 years...
  27. doi request reprint Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial
    Inder S Anand
    Cardiology 111 C, VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
    Circulation 122:1387-95. 2010
    ..Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure...
  28. ncbi request reprint Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Card Fail 13:331-9. 2007
    ..Whether the fixed-dose combination produces a further regression of LV remodeling when added to renin-angiotensin and sympathetic inhibitors has not been documented...
  29. ncbi request reprint Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study
    Daniel A Duprez
    Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, VCRC Room 270, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 50:835-9. 2007
    ....
  30. doi request reprint Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure
    Inder S Anand
    VA Medical Center, Cardiology 111 C, Minneapolis, Minn 55417, USA
    Circulation 120:1577-84. 2009
    ..Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness...
  31. ncbi request reprint Outcomes by gender in the African-American Heart Failure Trial
    Anne L Taylor
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 48:2263-7. 2006
    ..We therefore compared outcomes by gender and treatment...
  32. ncbi request reprint Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
    Inder S Anand
    VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
    Circulation 107:1278-83. 2003
    ..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial...
  33. doi request reprint Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations
    Daniel A Duprez
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
    J Am Soc Hypertens 5:401-9. 2011
    ..Identifying early disease in asymptomatic individuals provides a better guide to the need for preventive therapy than traditional risk factor assessment...
  34. ncbi request reprint What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Am Heart J 152:859.e1-8. 2006
    ..A preliminary trial is under way to evaluate the role of angiotensin receptor blockade as preventive treatment of individuals with early signs of vascular or cardiac disease...
  35. ncbi request reprint Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
    Anne L Taylor
    Department of Medicine Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
    N Engl J Med 351:2049-57. 2004
    ..We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy...
  36. ncbi request reprint Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1121-7. 2005
    ..Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb) over time or about the causes of anemia...
  37. ncbi request reprint Measuring endothelial function
    Christopher J Lockhart
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, Minneapolis, MN, 55455, USA
    Curr Diab Rep 6:267-73. 2006
    ..In this article, we critically appraise the use of different methodologies employed to study endothelial function as a surrogate marker of future cardiovascular risk...
  38. doi request reprint Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
    Inder S Anand
    VA Medical Center, Cardiology 111 C, One Veterans Drive, Minneapolis, MN 55417, USA
    Eur J Heart Fail 15:511-8. 2013
    ..This study was conducted to determine whether galectin-3, a β-galactoside-binding lectin, plays a role in the pathogenesis of heart failure (HF)...
  39. doi request reprint Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial
    Inder S Anand
    VA Medical Center, Cardiology, Minneapolis, MN 55417, USA
    Circ Heart Fail 1:34-42. 2008
    ..The aim of the present study was to investigate the relationship between the SBP-lowering effects of valsartan and its cardiovascular protective effects in this population...
  40. ncbi request reprint Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life
    Thomas S Rector
    Center for Chronic Disease Outcomes Research, Department of Veterans Affairs Medical Center, 152 2E, One Veterans Drive, Minneapolis, MN 55417, USA
    J Card Fail 12:87-92. 2006
    ..Hypothetically, most of the effects of heart failure on quality of life might be attributed to symptoms produced by the pathology. Relationships between measures of these concepts need to be quantified to test this conceptual model...
  41. doi request reprint Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Hypertens 21:248-56. 2008
    ..Trials designed to document such efficacy are currently underway...
  42. ncbi request reprint Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy
    Barry J Maron
    Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, and University of Minnesota, Minneapolis, MN 55407, USA
    Circulation 109:984-9. 2004
    ..Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for heart failure severity and outcome, predominantly in coronary heart disease with ventricular dilatation and systolic dysfunction...
  43. ncbi request reprint Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events
    Elizabeth Grey
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Am J Hypertens 16:265-9. 2003
    ..In this study, the predictive value of reduced elasticity of these arteries was evaluated by follow-up of subjects who underwent pulse contour analysis at the University of Minnesota...
  44. pmc The African-American Heart Failure Trial: background, rationale and significance
    Anne L Taylor
    University of Minnesota, Minneapolis, USA
    J Natl Med Assoc 94:762-9. 2002
    ..Besides additional testing of H+ISDN in HF, A-HeFT will be the first HF trial aimed at a subgroup of African American patients, as well as the first to use a new composite HF score as its primary efficacy endpoint...
  45. ncbi request reprint Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Adv Ther 24:1290-304. 2007
    ..Results from ongoing, large-scale, clinical endpoint trials will provide important additional information about the benefits of dual RAAS inhibition in patients at high risk for CV morbidity and mortality...
  46. ncbi request reprint Identifying early cardiovascular disease to target candidates for treatment
    Daniel A Duprez
    Cardiovascular Division, Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    J Clin Hypertens (Greenwich) 10:226-31. 2008
    ..Each test is individually scored, and the total disease score is the sum of all the test scores. A study is ongoing to compare the new disease score vs the classical Framingham risk estimate in the prediction of cardiovascular events...
  47. ncbi request reprint Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    J Card Fail 9:S197-8. 2003
  48. ncbi request reprint Determinants of radial artery pulse wave analysis in asymptomatic individuals
    Daniel A Duprez
    Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Am J Hypertens 17:647-53. 2004
    ....
  49. ncbi request reprint A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    J N Cohn
    Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, USA
    N Engl J Med 345:1667-75. 2001
    ..However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination...
  50. ncbi request reprint Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Cardiol 90:992-3. 2002
  51. ncbi request reprint Arterial stiffness as a risk factor for coronary atherosclerosis
    Daniel A Duprez
    Cardiovascular Division, VCRC Room 270, University of Minnesota, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA
    Curr Atheroscler Rep 9:139-44. 2007
    ..Promising study results show that measurement of arterial stiffness could become an important part of the routine assessment of patients in daily practice...
  52. ncbi request reprint Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial
    Jay N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Box 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Am J Hypertens 17:134-8. 2004
    ..The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians...
  53. ncbi request reprint Introduction to surrogate markers
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
    Circulation 109:IV20-1. 2004
  54. ncbi request reprint Blood pressure and arterial compliance in young adults: the Minnesota Children's Blood Pressure Study
    D K Arnett
    Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454 1015, USA
    Am J Hypertens 14:200-5. 2001
    ..008 mL/mm Hg change in C2. Data from the Minnesota Children's Blood Pressure Study indicate that systolic BP is inversely related to arterial compliance, particularly C1 (the large artery, or capacitive compliance)...
  55. ncbi request reprint Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators
    J N Cohn
    University of Minnesota Medical School, Box 508, 420 Delaware Street S E, Minneapolis, MN 55455, USA
    Eur J Heart Fail 2:439-46. 2000
    ..A total of 5010 patients with an ejection fraction <40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo...
  56. ncbi request reprint Relationship between C-reactive protein and arterial stiffness in an asymptomatic population
    D A Duprez
    Department of Medicine, Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, 55455, USA
    J Hum Hypertens 19:515-9. 2005
    ....
  57. ncbi request reprint Left ventricle and arteries: structure, function, hormones, and disease
    J N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, USA
    Hypertension 37:346-9. 2001
    ..Thus, progression of cardiovascular disease is largely a consequence of structural changes that are hormonally mediated and may be inhibited by drug therapy...
  58. doi request reprint Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction
    Michael D Miedema
    University of Minnesota Cardiovascular Division, Minneapolis, MN 55407, USA
    Am Heart J 164:259-67. 2012
    ..Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy...
  59. ncbi request reprint Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial
    Inder Anand
    Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, USA
    Lancet 364:347-54. 2004
    ..We aimed to measure the effects of long-term endothelin-blockade on left-ventricular (LV) remodelling and clinical outcomes in patients with chronic heart failure...
  60. ncbi request reprint Arterial compliance abnormalities in isolated systolic hypertension
    A Beltran
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA
    Am J Hypertens 14:1007-11. 2001
    ..This abnormality cannot be accurately assessed by pulse pressure alone...
  61. ncbi request reprint Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension
    Masood Gilani
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA Current address Bay Pines VA Hospital, St Petersburg, Florida, USA
    J Am Soc Hypertens 1:45-55. 2007
    ..Reduction in small artery compliance was a sensitive marker for this induced endothelial dysfunction and may serve as a useful marker for pre-hypertensive patients at risk for cardiovascular morbid events...
  62. ncbi request reprint New therapeutic strategies for heart failure: left ventricular remodeling as a target
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Card Fail 10:S200-1. 2004
    ..The growing evidence that structural remodeling represents the disease of heart failure has now fueled mechanical as well as pharmacologic approaches to inhibiting the remodeling...
  63. ncbi request reprint Endothelial dysfunction and the metabolic syndrome
    Gary E McVeigh
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Curr Diab Rep 3:87-92. 2003
    ..Noninvasive assessment of vascular health may also aid the clinical decision-making process by guiding therapeutic interventions to optimize vascular protection in the metabolic syndrome...
  64. ncbi request reprint Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making
    J N Cohn
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis 55455, USA
    Am J Hypertens 14:258S-263S. 2001
    ..Further research is needed to confirm whether this method offers a means of improving risk stratification and therapeutic decision making...
  65. ncbi request reprint Reduced vascular compliance as a marker for essential hypertension
    G E McVeigh
    Department of Medicine, University of Minnesota Medical School, Minneapolis
    Am J Hypertens 4:245-51. 1991
    ....
  66. ncbi request reprint Global structural ventricular remodeling: summation
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Card Fail 8:S269-70. 2002
  67. ncbi request reprint Beta-blockers for heart failure
    Jay N Cohn
    Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Card Fail 9:458. 2003
  68. ncbi request reprint Non-invasive studies of peripheral vascular compliance using a non-occluding photoplethysmographic method
    E A López-Beltrán
    Biomedical Engineering Program, University of Minnesota, USA
    Med Biol Eng Comput 36:748-53. 1998
    ..The results suggest that Cindex may be a useful noninvasive indicator of peripheral vascular compliance in humans...
  69. ncbi request reprint Heart failure: future treatment approaches
    J N Cohn
    University of Minnesota Medical School, Minneapolis 55455, USA
    Am J Hypertens 13:74S-78S. 2000
    ..The long-term solution to this clinical problem is to develop sensitive and reliable markers that can predict response in individual patients or monitor effectiveness of therapy...
  70. ncbi request reprint Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man
    J N Cohn
    Hypertension and Clinical Hemodynamics Section, Veterans Administration Hospital, Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA
    Circulation 38:151-7. 1968
    ..It is concluded that PLV-2 in small doses produces renal vasodilation and in larger doses preferential extra-renal vasoconstriction resulting in redistribution of blood flow to the kidney...
  71. ncbi request reprint Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Aldo P Maggioni
    ANMCO Research Center, Florence, Italy
    Am Heart J 149:548-57. 2005
    ..The aims of these subanalyses of Val-HeFT were to assess (a) the effects of valsartan in the prevention of AF, (b) the independent predictors of this event, and (c) the prognostic role of AF occurrence...
  72. ncbi request reprint Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Circulation 105:1797-803. 2002
    ..We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure...
  73. ncbi request reprint Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study
    Stefan D Anker
    Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
    Lancet 361:1077-83. 2003
    ..We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors...
  74. ncbi request reprint Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Clin Chem 52:1528-38. 2006
    ..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF...
  75. ncbi request reprint Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)
    Roberto Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 106:2454-8. 2002
    ..The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known...
  76. ncbi request reprint Sympathetic nervous system in heart failure
    Jay N Cohn
    Circulation 106:2417-8. 2002
  77. ncbi request reprint Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
    Aldo P Maggioni
    ANMCO Research Center, Florence, Italy
    J Am Coll Cardiol 40:1414-21. 2002
    ....
  78. ncbi request reprint Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study
    Maylene Wong
    VA Greater Los Angeles Healthcare System and University of California at, Los Angeles, California 90073, USA
    J Am Coll Cardiol 40:970-5. 2002
    ..The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy...
  79. ncbi request reprint African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology
    Joseph A Franciosa
    Zena and Michael A Wiener Cardiovascular Institute, Mt Sinai School of Medicine, New York, New York, USA
    J Card Fail 8:128-35. 2002
    ..Analysis of previous trials has shown that H+ISDN appears especially beneficial in African American patients...
  80. ncbi request reprint Techniques for studying arterial elastic properties
    Jay N Cohn
    Hypertension 39:e20. 2002
  81. ncbi request reprint Effect of Valsartan on hospitalization: results from Val-HeFT
    Peter Carson
    Department of Veterans Affairs, Medical Center, Washington, DC 20422, USA
    J Card Fail 9:164-71. 2003
    ..5% versus placebo (P <.001). This article analyzes all-cause and investigator-assessed HF hospitalization in Val-HeFT overall and in subgroups defined by preexisting HF therapy...
  82. ncbi request reprint Ventricular remodeling in heart failure: a credible surrogate endpoint
    Marvin A Konstam
    J Card Fail 9:350-3. 2003
  83. ncbi request reprint The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 12:375-80. 2006
    ..Here, we examined its prognostic value in a large population of patients with chronic heart failure...
  84. ncbi request reprint Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial
    Dennis M McNamara
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    J Am Coll Cardiol 48:1277-82. 2006
    ..We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT)...
  85. ncbi request reprint Incremental prognostic value of changes in B-type natriuretic peptide in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Am J Med 119:70.e23-30. 2006
    ..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial...
  86. ncbi request reprint The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial
    Jay N Cohn
    Rasmussen Center for Cardiovascular Disease Prevention at the University of Minnesota, USA
    J Law Med Ethics 34:552-4, 480. 2006
    ..Application of these findings need not be confined to the population studied, but the observation highlights the need for more precise ways to identify individual responsiveness to therapy...
  87. ncbi request reprint Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT
    Maylene Wong
    VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, USA
    Eur J Heart Fail 8:502-8. 2006
    ..Clinical trials emphasize mortality and morbidity endpoints...
  88. ncbi request reprint Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial
    Giuseppina Majani
    Salvatore Maugeri Foundation, Psychology Unit, Institute of Care and Scientific Research, Montescano, Pavia, Italy
    J Card Fail 11:253-9. 2005
    ..The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT)...
  89. ncbi request reprint Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)
    Lawrence Baruch
    Bronx VA Medical Center, Bronx, NY 10468, USA
    Am Heart J 148:951-7. 2004
    ..As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance...
  90. ncbi request reprint Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT
    Henry Krum
    Monash University Medical School, Alfred Hospital, Melbourne, Australia
    Eur J Heart Fail 6:937-45. 2004
    ..To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF)...
  91. ncbi request reprint Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data
    Maylene Wong
    Veterans Affairs Greater Los Angeles Healthcare System, and David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90073, USA
    J Am Coll Cardiol 43:2022-7. 2004
    ..The objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure...
  92. ncbi request reprint Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox
    S William Tam
    NitroMed, Inc, Lexington, Massachusetts 02421, USA
    Clin Pharmacokinet 46:885-95. 2007
    ....
  93. ncbi request reprint The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Eur Heart J 25:292-9. 2004
    ..Mainly because of small sample size, the predictive value of different NH has never been compared, while taking into account demographic, clinical and echocardiographic markers of risk in HF...
  94. ncbi request reprint Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial
    Jalal K Ghali
    University Health Center, Wayne State University, Detroit, MI 48201, USA
    Am J Cardiovasc Drugs 7:373-80. 2007
    ....
  95. ncbi request reprint Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial
    Lidia Staszewsky
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 13:797-804. 2007
    ..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure...
  96. ncbi request reprint Antihypertensive utility of perindopril in a large, general practice-based clinical trial
    Stevo Julius
    Division of Hypertension, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Hypertens (Greenwich) 6:10-7. 2004
    ..Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal...
  97. ncbi request reprint Myocardial structural effects of aldosterone receptor antagonism in heart failure
    Jay N Cohn
    J Am Coll Cardiol 50:597-9. 2007